gastric cancer
Conditions
Interventions
Oral supplementation of 2 packs of ProSure per day for 7 days before surgery and for 21 days after surgery
No nutritional supplementation was given perioperatively
Sponsors
non-profit organization KSATTS
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: i. Histologically proven adenocarcinoma of the stomach ii.Clinical T2-T4a and no distant metastasis iii.R0 resection is possible by open total gastrectomy iv.Enough oral intake v.Age ranging between 20 and 80. vi.ECOG performance status 0-1. vii.Not cancer of the remnant stomach viii.Suficient organ functions. iv.Written informed consent.
Exclusion criteria
Exclusion criteria: i.Treatment with drug including EPA (ethyl icosapentate) ii.Synchronous or metachronous cancer (synchronous multiple cancers in the stomach included). iii.Active inflammation which requires systemic treatment iv.Hemorrhagic tendency v.Lactose intolerance vi.Allergic reaction to milk and soy bean vii.Uncontrollable diabetes mellitus viii.Systemic treatment with corticosteroid ix.Unstable angina or cardiac infarction within 6 months x.Pulmonary disorder under oxygen xi.Woman with on-going pregnancy or breast-feeding, or contemplating pregnancy. xii.Mental disorders which may affect ability or willingness to provide informed consent or abide by the study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| body weight loss at 1 and 3 months after surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Relative performance of ProSure, weight loss of lean body at 1 and 3 months after surgery, the lowest serum albumin level, quality of life, incidence of surgical morbidity and mortality, and incidence of surgical site infection. | — |
Countries
Japan
Contacts
Public ContactTakaki Yoshikawa
Yokohama City University Medical Center Department of Gastrointestinal Surgery
Outcome results
None listed